Digest Network Come funziona
Network
/
Società
Ph
Non verificato

PharmaEssentia Corporation

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

15 comunicati stampa

Guarda tutti i comunicati
11/06/2026
Multimedialità
Mercato azionario
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
PharmaEssentia Expands North American Commercial Footprint with Acquisition of Canadian Partner FORUS Therapeutics
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
27/05/2026
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Mercato del lavoro
Industria
PharmaEssentia Appoints Eric Vogel as U.S. Head of Commercialization Ahead of Potential Launch of BESREMi® in Essential Thrombocythemia
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
27/04/2026
Taiwan's Representative to the United States Alexander Tah-ray Yui Visits PharmaEssentia's Puerto Rico Facility Alongside Puerto Rico Officials
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
02/04/2026
Mercato del lavoro
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
PharmaEssentia Signs Investment Agreement for New Manufacturing Facility in Puerto Rico
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
02/03/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
PharmaEssentia Announces Japan Approval of High-Dose Dosing Regimen for BESREMi®
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
09/02/2026
Industria
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Sanità
PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Support Global Growth of BESREMi®
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
07/01/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Attrezzature medico-sanitarie
Oncologia
Salute
Medicina - Varie
CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
06/01/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Attrezzature medico-sanitarie
Oncologia
Salute
Medicina - Varie
PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
19/12/2024
Web e Social Network
Fiere
Eventi
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
PharmaEssentia to Present at the Annual J.P. Morgan Healthcare Conference on January 16, 2025
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
05/12/2024
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
PharmaEssentia Appoints Joseph R. Horvat as Global Chief Commercial Officer
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0